Stockscreener 앱 받기
4.67%
전일 마감가:
$3.96
열려 있는:
$4
하루 거래량:
2.25M
Relative Volume:
0.57
시가총액:
$433.54M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.5335
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
+14.82%
1개월 성능:
-20.90%
6개월 성능:
-6.43%
1년 성능:
-43.30%
1일 변동 폭
$3.98
$4.3367
1주일 범위
$3.48
$4.53
52주 변동 폭
$2.90
$7.83
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.155 | 413.20M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.17 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
798.55 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.04 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.60 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.17 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA flags new liver disease drug for faster review after promising early data - Stock Titan
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks
Altimmune announces CEO transition - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares - MarketBeat
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit - Citeline News & Insights
Altimmune Director Jerome Benedict Durso Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha
Altimmune Slides As Insider Purchases Lose Another US$15k - 富途牛牛
Altimmune Stock Plummets After Disappointing Trial Results - timothysykes.com
Would You Still Hold Altimmune Stock If It Fell Another 30%? - Trefis
Can Altimmune Inc. stock hit analyst price targetsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
How Altimmune Inc. stock compares to market leadersPortfolio Risk Report & Weekly Setup with High ROI Potential - Улправда
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Price Targets & Community Consensus Trade Signals - Улправда
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASHSlideshow (NASDAQ:ALT) 2025-12-19 - Seeking Alpha
Why Is Altimmune Stock Up Over 10% Before The Bell? - Stocktwits
Altimmune (ALT) Shares Plunge Following Phase 2b MASH Trial Resu - GuruFocus
ALT Stock Surge: Should You Act? - StocksToTrade
Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed - MSN
Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating - TipRanks
Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target - TipRanks
Altimmune stock tumbles after MASH drug trial data By Investing.com - Investing.com Nigeria
Altimmune stock tumbles after MASH drug trial data - Investing.com
Transcript : Altimmune, Inc.Special Call - marketscreener.com
Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail - Endpoints News
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jorkasky Diane | Director |
Dec 29 '25 |
Buy |
3.80 |
527 |
2,003 |
527 |
| GILL JOHN | Director |
Dec 23 '25 |
Buy |
4.10 |
12,500 |
51,250 |
12,500 |
| Durso Jerome Benedict | Director |
Dec 22 '25 |
Buy |
4.13 |
12,500 |
51,569 |
12,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Nov 11 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
28,750 |
| Sohn Catherine A. | Director |
Mar 17 '25 |
Buy |
5.78 |
1,000 |
5,784 |
1,000 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
0.70%
자본화:
|
볼륨(24시간):